Cytosorbents Corp — Director's Dealing 2021

Jan 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cytosorbents Corp (CTSO)
CIK: 0001175151
Period of Report: 2020-12-31

Reporting Person: BLOCH KATHLEEN P. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-31	Common Stock	M	7857	$5.60	Acquired	333013	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-31	Stock Option (right to buy)	$5.60	M	7857	Disposed	2027-02-24	Common Stock (7857)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	21000	Indirect

Footnotes

F1: Includes: (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the Company's 2014 Long-Term Incentive Plan (the "Plan"): (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018;

F2: (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date), and will be settled into common stock, par value $0.001 per share (the "Common Stock") of the Company upon vesting: (a) 28,667 RSUs granted on February 28, 2020 and unvested as of the date hereof, (b) 14,334 RSUs granted on July 22, 2019 and unvested as of the date hereof and (c) 1,358 RSUs granted on March 4, 2019 and unvested as of the date hereof; and

F3: (iii) 107,154 shares of Common Stock owned by the Reporting Person.

F4: Includes (i) 10,000 shares held by the Reporting Person's husband in a 401(k) account and (ii) 11,000 shares held by the Reporting Person's husband in an IRA account. The Reporting Person may be deemed the beneficial owner of such shares.

F5: These stock options were originally granted on February 24, 2017 and became exercisable upon achievement of certain performance goals as determined in the discretion of the Compensation Committee of the Board of Directors of the Company.